The plasma-derived drugs market is poised to attain a CAGR of 6.5% during the forecast period, up from US$ 37 Bn in 2022 to reach a valuation of US$ 74 Bn by 2032.
Demand for plasma-derived drugs rises as plasma antibodies, immunoglobulins, clotting factors, fibrinogens, and other plasma-derived medicinal compounds can be extracted from plasma that has a wide range of applications and advantages.
| Attributes | Details |
| Plasma Derived Drugs Market CAGR | 6.5% |
| Plasma Derived Drugs Market (2022) | US$ 37 Bn |
| Plasma Derived Drugs Market (2032) | US$ 53 Bn |
Plasma-derived medicinal products (PDMPs) are used in medical treatment and prevention to treat autoimmune disorders and bleeding emergencies. Hence, the sales of plasma-derived drugs are expected to spike.
In addition, the demand for plasma-derived drugs can be attributed to chronic conditions like hemophilia, congenital and acquired immunodeficiencies, etc., which can also be treated with the aid of plasma-derived drugs.
Furthermore, increasing regulatory approvals for plasma-derived medicines are expected to drive the sales of plasma derived drugs during the forecast period.
For example, Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, announced in January 2022 that the National Medical Products Administration (NMPA) of China granted BPL a license to market ALBUMINEX 25 percent product in China.
Higher sales of plasma derived drugs can be attributed to key market players' increased adoption of inorganic strategies, such as agreements and collaborations.
The rise in the prevalence of rare and chronic diseases creates a more lucrative opportunity for market manufacturers to enlarge their plasma derived drugs market share.
Immunoglobulin products, albumin products, clotting factors, and a few others are currently available in the plasma-derived drugs market that significantly aids in the treatment of various diseases, which in turn, scales up the sales of plasma derived drugs.
The rising demand for plasma derived drugs is also due to the unique mechanism associated with each plasma-derived drug and its usage to achieve better clinical outcomes.
Demand for plasma derived drugs goes up as the cost of manufacturing plasma derived drugs is more than four times the cost of manufacturing other pharmaceuticals.
The business model for plasma-derived drugs is different than what is present in the pharmaceutical market.
The clear-cut research process and drug discovery process is different; moreover, the industry requires a more vigorous approach to create a balance in the sales, thereby dwindling the sales of plasma derived drugs.
Manufacturers of plasma-derived drugs spend the majority of their resources on manufacturing each drug, and the same is making them give second thoughts, which may result in lower plasma derived drugs market share.
Sales of plasma derived drugs are lowered due to threats present in developing plasma-derived drugs.
Furthermore, threats of emerging pathogens greatly affect the production cost for each manufacturer in the plasma derived drugs market.
The manufacturing of plasma-derived drugs takes a significant time, it could go from eight months to more than twelve months, and any shortcomings during the period can create serious consequences for the company affecting the market dynamics.
The same is considered as one of the factors adversely affecting the demand for plasma derived drugs as well as sales of plasma derived drugs during the forecast period.
The demand for plasma derived drugs is impacted by government policies that present to increase the number of blood banks.
Plasma policies aim to make the availability, and accessibility of plasma to a greater extent, and such aim significantly influences the sales of plasma derived drugs.
Demand for plasma derived drugs surges on account of moving the available adequate amount of plasma throughout different corners for better.
Geographically, the plasma derived drugs market is segmented into seven regions, viz. South Asia, East Asia, Europe, Latin America, North America, Oceania, and the Middle East and Africa.
Each country is equally important to drive the demand for plasma derived drugs. Advanced or emerging healthcare settings help in restoring the market and increase the reach to a wider section of patients in need.
Blood donation is an important part of the sales of plasma derived drugs. The greater number of blood units would result in a greater number of such products and hence, higher demand for plasma derived drugs.
The developed economies play an important role in the industry as well as the overall demand for plasma derived drugs, but emerging economies are also moving at a good pace.
The North American region is estimated to have a significant plasma derived drugs market share, owing to its quality infrastructure supporting the need for plasma-derived drugs.
They are followed by Europe, East Asia, and Oceania. The South Asia plasma-derived drugs market, would translate as a market exhibiting rising sales of plasma derived drugs.
The region’s market is expected to provide lucrative opportunities for industry experts, thereby enlarging their plasma derived drugs market share, coupled with a present change in adoption and growth in the general pharmaceutical market.
The key players involved in the market of plasma derived drugs include Grifols, S.A., Octa Pharma, Antaris Pharma, and CSL Limited.
The present market structure of plasma-derived drugs is expected to change with efforts and research present in the clinical phase coupled with player’s effort to augment their plasma derived drugs market share.
Kamada Pharmaceuticals, China Biologic Products Holdings, Bio Products Laboratory Ltd., Inc., Shanghai RAAS, Kedrion, ADMA Biologics Inc., and Biotest AG are some other major players in the global plasma derived drugs market.
| Report Attribute | Details |
| Growth rate | CAGR of 6.5% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2014 - 2020 |
| Forecast period | 2022 - 2032 |
| Quantitative units | Revenue in USD billion, volume in kilotons, and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis |
| Segments covered | Product, application, region |
| Regional scope | North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand |
| Country scope | U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa |
| Key companies profiled | Kamada Pharmaceuticals, China Biologic Products Holdings, Bio Products Laboratory Ltd., Inc., Shanghai RAAS, Kedrion, ADMA Biologics Inc., and Biotest AG |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
The plasma derived drugs market is anticipated to record a CAGR of 6.5% during the forecast period.
The plasma derived drugs market size accounted for about US$ 33 Bn in 2019.
Grifols, S.A., Octa Pharma, Antaris Pharma, and CSL Limited. are some notable players in the plasma derived drugs market.
Explore Similar Insights
Plasma-Derived Drugs Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
